L’entreprise aimerait remercier @SimB pour sa contribution à tous les niveaux de warrants!
Lol j’ai hâte de voir le breakdown voir si je suis le seul qui a aussi exercé des 0.30$
J’ai des membres de la famille affectés par la maladie alors je soutiens la cause…!
“We are pleased to close another successful financing,” said Executive Chairman Gene Williams. “This will allow us to continue moving full speed ahead with our lead program PMN310, which selectively targets the toxic oligomers of amyloid beta, a root cause of Alzheimer’s disease. We will also be able to accelerate our development of a broad portfolio of antibodies that selectively target different toxic oligomers including Alpha synuclein, TDP43, Tau and SOD1 in other neurodegenerative diseases, capitalizing on our unique and valuable technology platform.”
Each Unit consisted of one ProMIS common share and one-half of a ProMIS share purchase warrant. Each warrant will entitle the holder thereof to purchase one ProMIS common share at an exercise price of CDN$0.48 at any time for five years, subject to earlier expiry on 30 days notice if, at any time after four months from closing, the twenty-day volume-weighted average trading price of ProMIS’ common shares is greater than CDN$1.00.
ProMIS will compensate finders in respect of a portion of the non-US subscribers through 7% cash fees and a total of 339,360 finder warrants having the same terms as the Unit warrants. Noble Capital Markets, Inc., which acted as placement agent for subscribers in the United States, will receive a cash commission equal to 7% of the gross proceeds placed with its US subscribers and will be issued compensation warrants to purchase up to 215,871 common shares for a period of five years at an exercise price of CDN$0.48 per share.
Ça commence à devenir de plus en plus concret pour ProMIS.
Couverture de Zacks Small Cap Research. Quand même, une prédiction de lancement de produits en 2027 avec un price target de 7$. Faut avoir un horizon long terme lol.
By John Vandermosten, CFA
READ THE FULL PMN.TO RESEARCH REPORT
We are initiating coverage of ProMIS Neurosciences Inc. (TSE:PMN.TO) (OTC:ARFXF) with a CAD$7.00 price target based on our forecast for product sales after a 2027 launch of its lead candidate PMN310 in the United States, EU and rest of world. The company is developing a monoclonal antibody (mAb) that targets epitopes specific to toxic oligomers implicated in the development of Alzheimer’s Disease (AD). The company’s lead candidate is currently in pre-clinical development and is expected to begin Phase I trials in 2019. In recent years there have been numerous failures in the AD space and no drug or biologic has ever been approved as a cure for the disease. Despite the poor success rate, much has been learned in the last decades from unsuccessful trials and adjacent research work. Efforts have narrowed down the target to amyloid-beta (Aβ), which comes in several forms. Consensus has built in recent years directing the focus towards toxic oligomers as the cause of AD, which are small clumps of monomers that accumulate in the brain and kill neurons. ProMIS’ PMN310 is able to exclusively target this form of Aβ and is built on a peptide backbone that avoids common side effects.
Le vidéo de 10 minutes est intéressant et démontre bien la différentiation de ProMIS par rapport aux deux autres anticorps ayant eu du succès en Phase II.
$6.8M en encaisse suite au dernier placement privé. ProMIS devrait pouvoir traverser environ 3 trimestres avec cet argent et devra vraisemblablement lever une dernière grosse ronde de financement au début 2019 afin d’initier son étude clinique de phase I (c’est ma vision de la situation, je n’ai pas parlé au management récemment).
Dr. Kupiec to leverage neurodegenerative experience from prior senior positions at Pfizer and Sanofi-Synthelabo
TORONTO and CAMBRIDGE, MA, Sept. 13, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of James Kupiec, MD, to the position of Chief Medical Officer. In this newly created role, reporting to both the Executive Chairman and CEO, Dr. Kupiec will lead ProMIS’ clinical development programs, in particular the initiation of clinical trials of PMN310 for the treatment of Alzheimer’s disease (AD) in the second half of 2019.
“We are very pleased to welcome Dr. Kupiec to our senior management team,” said ProMIS Executive Chairman, Eugene Williams. “Jim’s expertise and experience as an accomplished leader of clinical development programs in Alzheimer’s disease and other neurodegenerative disorders will be a great source of strength for ProMIS. He will not only provide outstanding clinical trial leadership but will also play a significant role in interaction with regulatory authorities, key neuroscience opinion leaders and potential pharmaceutical partners.”
Dr. Kupiec is a physician-scientist with over two decades of broad, hands-on experience in translational, early- and late-stage neuroscience drug development in the pharmaceutical industry.
“I am thrilled to join the ProMIS leadership team at this critical stage,” said Dr. Kupiec. “ProMIS’ innovative approach selectively targeting toxic oligomers for treatment of neurodegenerative disorders is unique and provides a real opportunity for transformative, novel therapies. I am delighted to contribute to the advancement of the ProMIS clinical pipeline.”
Dr. Kupiec most recently served as VP, Global Clinical Leader for Parkinson’s Disease, and Clinical Head of the Neuroscience Research Unit in Cambridge for Pfizer, Inc. He joined Pfizer in 2000 after seven years at Sanofi-Synthelabo, and two years with Ciba-Geigy Pharmaceuticals. During his career at Pfizer, he had extensive governance, business development, alliance and leadership responsibilities. Much of his work during the last decade has focused on developing potential disease modifying and symptomatic therapies for Alzheimer’s disease and other neurodegenerative disorders, including monoclonal antibodies. As project leader and Clinical Head, Dr. Kupiec created and implemented global drug development strategies, met with worldwide regulatory authorities, and chaired numerous joint development committees with other pharmaceutical companies.
He earned his BS with Honors in Biochemistry at Stony Brook University and his MD from the Albert Einstein College of Medicine. He completed his residency training at the Strong Memorial Hospital, University of Rochester School of Medicine, and is certified by the American Board of Internal Medicine.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information please consult the Company’s website at: www.promisneurosciences.com
L’entreprise continue d’attirer des investisseurs avec les bons vieux warrants 5 ans!
Bon matin avez vous vue passé une nouvelle ce matin.ouch -30%
Voilà la raison:
Le traitement développé par ProMIS est quelque peu différent, mais disons que ce n’est pas très bon signe.
Communiqué de presse de ProMIS: Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer’s Disease
À voir le bilan et le rythme auquel l’entreprise brule de l’argent, j’ai l’impression qu’un autre financement sera annoncé sous peu.
PMN s’attend à aller en clinical trial bientôt? Ils en parlent dans le communiqué mais sans date approximative.
Si ma mémoire est bonne, l’objectif est dans les environs de mi-2020 pour une phase 1 et 2021-2022 pour une phase 2 (à vérifier, j’y vais seulement de mémoire).